DK1688488T3 - Bispecifikt antistof som erstatning for faktor III - Google Patents

Bispecifikt antistof som erstatning for faktor III

Info

Publication number: DK1688488T3
Authority: DK; Denmark
Prior art keywords: bispecific antibody; blood coagulation; coagulation factor; factor iii; replace
Prior art date: 2003-10-10

Application number

DK04792180.4T

Other languages

English (en)

Inventor

Kunihiro Hattori

Tetsuo Kojima

Taro Miyazaki

Tetsuhiro Soeda

Original Assignee

Chugai Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-10

Filing date

2004-10-08

Publication date

2011-09-26

2003-10-14 Priority claimed from PCT/JP2003/013123 external-priority patent/WO2005035754A1/ja

2004-10-08 Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd

2011-09-26 Application granted granted Critical

2011-09-26 Publication of DK1688488T3 publication Critical patent/DK1688488T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Hematology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)

DK04792180.4T 2003-10-10 2004-10-08 Bispecifikt antistof som erstatning for faktor III DK1688488T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
PCT/JP2003/013062 WO2005035753A1 (ja)	2003-10-10	2003-10-10	機能蛋白質を代替する二重特異性抗体
PCT/JP2003/013123 WO2005035754A1 (ja)	2003-10-14	2003-10-14	機能蛋白質を代替する二重特異性抗体
PCT/JP2004/014911 WO2005035756A1 (ja)	2003-10-10	2004-10-08	機能蛋白質を代替する二種特異性抗体

Publications (1)

Publication Number	Publication Date
DK1688488T3 true DK1688488T3 (da)	2011-09-26

Family

ID=34430861

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK16162353.3T DK3085783T3 (da)	2003-10-10	2004-10-08	Bispecifikt antistof som substitution for funktionelle proteiner
DK04792180.4T DK1688488T3 (da)	2003-10-10	2004-10-08	Bispecifikt antistof som erstatning for faktor III

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK16162353.3T DK3085783T3 (da)	2003-10-10	2004-10-08	Bispecifikt antistof som substitution for funktionelle proteiner

Country Status (23)

Country	Link
US (1)	US8062635B2 (da)
EP (3)	EP1688488B9 (da)
JP (2)	JP5438880B2 (da)
KR (2)	KR101361437B1 (da)
CN (1)	CN1890369B (da)
AT (1)	ATE518952T1 (da)
AU (2)	AU2003271174A1 (da)
BR (1)	BRPI0415230B1 (da)
CA (1)	CA2541671C (da)
DK (2)	DK3085783T3 (da)
ES (2)	ES2865152T3 (da)
HU (1)	HUE053833T2 (da)
IL (1)	IL174794A (da)
MX (1)	MXPA06003831A (da)
NO (2)	NO345624B1 (da)
NZ (1)	NZ546509A (da)
PL (1)	PL3085783T3 (da)
PT (1)	PT3085783T (da)
RU (1)	RU2339696C2 (da)
SI (1)	SI3085783T1 (da)
TW (1)	TW200514790A (da)
UA (1)	UA95438C2 (da)
WO (2)	WO2005035753A1 (da)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
GB0300571D0 (en) *	2003-01-10	2003-02-12	Imp College Innovations Ltd	Modification of feeding behaviour
WO2004111233A1 (ja)	2003-06-11	2004-12-23	Chugai Seiyaku Kabushiki Kaisha	抗体の製造方法
AU2003271174A1 (en)	2003-10-10	2005-04-27	Chugai Seiyaku Kabushiki Kaisha	Double specific antibodies substituting for functional protein
WO2005035754A1 (ja) *	2003-10-14	2005-04-21	Chugai Seiyaku Kabushiki Kaisha	機能蛋白質を代替する二重特異性抗体
US8187595B2 (en)	2004-05-07	2012-05-29	The University Of North Carolina At Chapel Hill	Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
CA2582194A1 (en)	2004-10-05	2006-04-20	Neuralab Limited	Methods and compositions for improving recombinant protein production
PE20061329A1 (es)	2004-12-15	2006-12-08	Neuralab Ltd	Anticuerpos ab humanizados para mejorar la cognicion
CN101198698B (zh)	2005-03-31	2014-03-19	中外制药株式会社	通过调节多肽缔合制备多肽的方法
CA2603264C (en) *	2005-04-08	2017-03-21	Chugai Seiyaku Kabushiki Kaisha	Antibody substituting for function of blood coagulation factor viii
EP2009101B1 (en)	2006-03-31	2017-10-25	Chugai Seiyaku Kabushiki Kaisha	Antibody modification method for purifying bispecific antibody
CN104761637B (zh) *	2006-03-31	2021-10-15	中外制药株式会社	调控抗体血液动力学的方法
JP2009274958A (ja) *	2006-08-31	2009-11-26	Nara Prefecture	血液凝固第ｖｉｉｉ因子の活性化を促進する抗体
ES2628395T3 (es)	2007-08-15	2017-08-02	Bayer Pharma Aktiengesellschaft	Anticuerpo regulado por proteasa
EP3415529B1 (en)	2007-09-26	2020-11-04	Chugai Seiyaku Kabushiki Kaisha	Modified antibody constant region
CN101874042B9 (zh)	2007-09-26	2019-01-01	中外制药株式会社	利用cdr的氨基酸取代来改变抗体等电点的方法
JO3076B1 (ar)	2007-10-17	2017-03-15	Janssen Alzheimer Immunotherap	نظم العلاج المناعي المعتمد على حالة apoe
BRPI0821110B8 (pt) *	2007-12-05	2021-05-25	Chugai Pharmaceutical Co Ltd	anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
EP2275443B1 (en)	2008-04-11	2015-12-02	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US8609817B2 (en) *	2008-08-06	2013-12-17	Eli Lilly And Company	Anti-hepcidin-25 selective antibodies and uses thereof
TWI440469B (zh) *	2008-09-26	2014-06-11	Chugai Pharmaceutical Co Ltd	Improved antibody molecules
US9067981B1 (en)	2008-10-30	2015-06-30	Janssen Sciences Ireland Uc	Hybrid amyloid-beta antibodies
ES2733067T3 (es) *	2008-12-19	2019-11-27	Macrogenics Inc	Diacuerpos covalentes y usos de los mismos
TWI682995B (zh)	2009-03-19	2020-01-21	日商中外製藥股份有限公司	抗體恆定區域改變體
WO2010107110A1 (ja)	2009-03-19	2010-09-23	中外製薬株式会社	抗体定常領域改変体
RU2011151069A (ru)	2009-05-15	2013-06-20	Чугаи Сейяку Кабусики Кайся	Анти-axl антитело
PT3023438T (pt)	2009-09-03	2020-05-08	Merck Sharp & Dohme	Anticorpos anti-gitr
JP5837821B2 (ja)	2009-09-24	2015-12-24	中外製薬株式会社	抗体定常領域改変体
AR080428A1 (es)	2010-01-20	2012-04-11	Chugai Pharmaceutical Co Ltd	Formulaciones liquidas estabilizadas contentivas de anticuerpos
US10435458B2 (en)	2010-03-04	2019-10-08	Chugai Seiyaku Kabushiki Kaisha	Antibody constant region variants with reduced Fcgammar binding
JO3330B1 (ar) *	2010-06-10	2019-03-13	Lilly Co Eli	الأجسام المضادة cgrp
KR101962483B1 (ko)	2010-11-17	2019-03-29	추가이 세이야쿠 가부시키가이샤	혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
TWI654204B (zh)	2010-11-30	2019-03-21	Chugai Seiyaku Kabushiki Kaisha	具有鈣依存性的抗原結合能力之抗體
JP5766296B2 (ja)	2010-12-23	2015-08-19	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
WO2012085113A1 (en)	2010-12-23	2012-06-28	Roche Diagnostics Gmbh	Binding agent
EP2659275B1 (en) *	2010-12-23	2017-11-22	Roche Diagnostics GmbH	Detection of a polypeptide dimer by a bivalent binding agent
CN103384825B (zh)	2010-12-23	2017-05-24	霍夫曼-拉罗奇有限公司	通过二价结合剂检测经翻译后修饰的多肽
EP2662385A4 (en)	2011-01-07	2015-11-11	Chugai Pharmaceutical Co Ltd	METHOD FOR IMPROVING THE PHYSICAL PROPERTIES OF ANTIBODIES
CA2827923C (en)	2011-02-25	2021-11-23	Chugai Seiyaku Kabushiki Kaisha	Fc.gamma.riib-specific fc antibody
TW201817744A (zh)	2011-09-30	2018-05-16	日商中外製藥股份有限公司	具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
US20150050269A1 (en)	2011-09-30	2015-02-19	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
ES2732712T3 (es)	2011-10-31	2019-11-25	Chugai Pharmaceutical Co Ltd	Molécula de unión a antígeno que tiene una conjugación regulada entre la cadena pesada y la cadena ligera
EP2821415B1 (en) *	2012-02-29	2021-03-31	Otsuka Pharmaceutical Co., Ltd.	Anti-lipoarabinomannan antibody and immunoassay for acid-fast bacillary infection using the antibody
NZ631565A (en)	2012-03-14	2016-07-29	Regeneron Pharma	Multispecific antigen-binding molecules and uses thereof
CA2881966C (en)	2012-08-24	2020-10-06	The Regents Of The University Of California	Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
HK1213904A1 (zh)	2012-08-31	2016-07-15	The University Of North Carolina At Chapel Hill	用於增强或抑制胰島素樣生長因子1(igf-1)的單克隆抗體
CA2886326C (en) *	2012-09-28	2021-11-02	Chugai Seiyaku Kabushiki Kaisha	Method for evaluating blood coagulation reaction
CN105764922B (zh)	2013-09-27	2020-07-17	中外制药株式会社	多肽异源多聚体的制备方法
US10035847B2 (en)	2013-10-02	2018-07-31	The Rockefeller University	Amyloid protofibril antibodies and methods of use thereof
TW201625299A (zh)	2014-06-20	2016-07-16	Chugai Pharmaceutical Co Ltd	用於因第ｖｉｉｉ凝血因子及／或活化的第ｖｉｉｉ凝血因子的活性降低或欠缺而發病及／或進展的疾病之預防及／或治療之醫藥組成物
GB201412658D0 (en)	2014-07-16	2014-08-27	Ucb Biopharma Sprl	Molecules
TWI701435B (zh)	2014-09-26	2020-08-11	日商中外製藥股份有限公司	測定ｆｖｉｉｉ的反應性之方法
TWI700300B (zh) *	2014-09-26	2020-08-01	日商中外製藥股份有限公司	中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
MA40764A (fr)	2014-09-26	2017-08-01	Chugai Pharmaceutical Co Ltd	Agent thérapeutique induisant une cytotoxicité
NZ730607A (en)	2014-12-19	2022-07-01	Chugai Pharmaceutical Co Ltd	Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
SG10201710322VA (en)	2014-12-19	2018-02-27	Chugai Pharmaceutical Co Ltd	Anti-c5 antibodies and methods of use
WO2016125495A1 (en)	2015-02-05	2016-08-11	Chugai Seiyaku Kabushiki Kaisha	Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
TWI873632B (zh)	2015-02-27	2025-02-21	日商中外製藥股份有限公司	Il-6受體抗體用於製備醫藥組成物的用途
US11142587B2 (en)	2015-04-01	2021-10-12	Chugai Seiyaku Kabushiki Kaisha	Method for producing polypeptide hetero-oligomer
AU2016248817A1 (en) *	2015-04-17	2017-08-17	F. Hoffmann-La Roche Ag	Combination therapy with coagulation factors and multispecific antibodies
JP2018123055A (ja) *	2015-04-24	2018-08-09	公立大学法人奈良県立医科大学	血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｘｉ因子（ｆｘｉ）異常症の予防および／または治療に用いられる医薬組成物
FR3038517B1 (fr)	2015-07-06	2020-02-28	Laboratoire Francais Du Fractionnement Et Des Biotechnologies	Utilisation de fragments fc modifies en immunotherapie
MY189159A (en)	2015-07-06	2022-01-29	Regeneron Pharma	Multispecific antigen-binding molecules and uses thereof
GB201601077D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibody molecule
GB201601073D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibodies
CN108271372B (zh)	2015-09-18	2021-07-09	中外制药株式会社	Il-8-结合抗体及其应用
GB201521382D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Antibodies
WO2017110981A1 (en)	2015-12-25	2017-06-29	Chugai Seiyaku Kabushiki Kaisha	Anti-myostatin antibodies and methods of use
WO2017110980A1 (ja)	2015-12-25	2017-06-29	中外製薬株式会社	増強された活性を有する抗体及びその改変方法
SG11201803989WA (en)	2015-12-28	2018-06-28	Chugai Pharmaceutical Co Ltd	Method for promoting efficiency of purification of fc region-containing polypeptide
IL260937B2 (en)	2016-02-06	2024-07-01	Epimab Biotherapeutics Inc	Fabs-in-tandem immunoglobulin and uses thereof
CA3016424A1 (en)	2016-03-14	2017-09-21	Chugai Seiyaku Kabushiki Kaisha	Cell injury inducing therapeutic drug for use in cancer therapy
ES3055961T3 (en)	2016-04-28	2026-02-17	Chugai Pharmaceutical Co Ltd	Antibody-containing preparation
WO2017190079A1 (en)	2016-04-28	2017-11-02	Regeneron Pharmaceuticals, Inc.	Methods of making multispecific antigen-binding molecules
EP3474854A4 (en)	2016-06-27	2020-02-19	The Regents of The University of California	CANCER TREATMENT COMBINATIONS
CN109415444B (zh)	2016-07-29	2024-03-01	中外制药株式会社	显示增加的备选fviii辅因子功能活性的双特异性抗体
BR112019001902A2 (pt)	2016-08-05	2019-07-09	Chugai Seiyaku Kabushiki Kaisha	composição para profilaxia ou tratamento de doenças relacionadas à il-8
EP3509637B1 (en)	2016-09-06	2024-11-27	Chugai Seiyaku Kabushiki Kaisha	Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
CN110662770A (zh) *	2016-11-23	2020-01-07	比奥维拉迪维治疗股份有限公司	结合凝血因子ix和凝血因子x的双特异性抗体
KR20190112747A (ko) *	2017-02-01	2019-10-07	노보 노르디스크 에이/에스	응고촉진 항체
EP3603670A4 (en)	2017-03-31	2021-03-10	Public University Corporation Nara Medical University	MEDICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF BLOOD CLOG FACTOR IX ANOMALY WITH A MULTI-SPECIFIC ANTIGIBINDING MOLECULAR FUNCTION OF BLOOD CLOTHING FACTOR VIII
US11851486B2 (en)	2017-05-02	2023-12-26	National Center Of Neurology And Psychiatry	Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
ES3065816T3 (en)	2017-06-07	2026-05-08	Regeneron Pharma	Compositions and methods for internalizing enzymes
GB201709970D0 (en)	2017-06-22	2017-08-09	Kymab Ltd	Bispecific antigen-binding molecules
JP6496095B1 (ja) *	2017-09-29	2019-04-03	中外製薬株式会社	血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）補因子機能代替活性を有する多重特異性抗原結合分子および当該分子を有効成分として含有する薬学的製剤
TW202600611A (zh)	2017-11-01	2026-01-01	日商中外製藥股份有限公司	生物活性降低之抗體變異體與同功型
CN111386285B (zh) *	2017-11-15	2024-08-27	诺和诺德股份有限公司	增强fx活化的因子x结合物
CN112074538B (zh)	2018-04-30	2024-10-18	瑞泽恩制药公司	结合her2和/或aplp2的抗体和双特异性抗原结合分子、其缀合物和用途
US12060425B2 (en)	2018-05-03	2024-08-13	Shanghai Epimab Biotherapeutics Co., Ltd.	High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins made therefrom
BR112020023145A2 (pt)	2018-05-17	2021-02-02	Regeneron Pharmaceuticals, Inc.	anticorpo anti-cd63 ou fragmento de ligação ao antígeno do mesmo, molécula de ligação ao antígeno biespecífica, proteína terapêutica de múltiplos domínios, polinucleotídeo composição farmacêutica, e, composto
US12493033B2 (en)	2018-06-04	2025-12-09	Chugai Seiyaku Kabushiki Kaisha	Method for detecting bi-specific antibody complex
FR3082427B1 (fr)	2018-06-14	2020-09-25	Lab Francais Du Fractionnement	Combinaison de facteur vii et d'un anticorps bispecifique anti-facteurs ix et x
US11220554B2 (en) *	2018-09-07	2022-01-11	Novo Nordisk A/S	Procoagulant antibodies
CN112513096B (zh) *	2018-08-01	2023-08-25	诺和诺德股份有限公司	改进的促凝血抗体
WO2020056334A1 (en) *	2018-09-14	2020-03-19	University Of New England	Methods and diagnostics for cancer detection and treatment monitoring
US20220064327A1 (en)	2018-12-21	2022-03-03	Kymab Limited	Fixaxfx bispecific antibody with common light chain
PE20212262A1 (es) *	2019-04-17	2021-11-29	Novo Nordisk As	Anticuerpos biespecificos
CN113939541A (zh) *	2019-05-15	2022-01-14	科马布有限公司	改进的λ抗体
CN114599391A (zh)	2019-10-11	2022-06-07	中外制药株式会社	可用于预防和/或治疗获得性血友病a的药物组合物，以及包含所述药物组合物的产品
TWI745114B (zh)	2019-10-11	2021-11-01	日商中外製藥股份有限公司	用於後天性血友病a之預防及/或治療之醫藥組成物、及包含該醫藥組成物之製品
WO2021129656A1 (en) *	2019-12-24	2021-07-01	Dizal (Jiangsu) Pharmaceutical Co., Ltd.	Novel anti-fgfr2b antibodies
JP2023106635A (ja)	2020-04-17	2023-08-02	中外製薬株式会社	二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
EP4155405A4 (en) *	2020-05-22	2024-07-03	Chugai Seiyaku Kabushiki Kaisha	Antibody for neutralizing substance having coagulation factor viii (f.viii) function-substituting activity
TWI872251B (zh)	2020-05-29	2025-02-11	日商中外製藥股份有限公司	含有抗體製劑
CN112794903B (zh) *	2021-04-14	2021-06-25	广州市雷德生物科技有限公司	一种特异性结合IFN-γ的抗体及其应用
US20250066436A1 (en)	2021-12-22	2025-02-27	Royal College Of Surgeons In Ireland	A conjugate for use in localising a molecule to the vascular endothelium
WO2025076507A1 (en) *	2023-10-06	2025-04-10	The Children's Hospital Of Philadelphia	Engineered proteins and methods of use thereof
GB202316779D0 (en) *	2023-11-01	2023-12-13	Ucl Business Ltd	Antigen binding protein

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4208479A (en) *	1977-07-14	1980-06-17	Syva Company	Label modified immunoassays
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
US4474893A (en)	1981-07-01	1984-10-02	The University of Texas System Cancer Center	Recombinant monoclonal antibodies
US4444878A (en) *	1981-12-21	1984-04-24	Boston Biomedical Research Institute, Inc.	Bispecific antibody determinants
HUT35524A (en)	1983-08-02	1985-07-29	Hoechst Ag	Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4945050A (en)	1984-11-13	1990-07-31	Cornell Research Foundation, Inc.	Method for transporting substances into living cells and tissues and apparatus therefor
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
JPH06104071B2 (ja) *	1986-08-24	1994-12-21	財団法人化学及血清療法研究所	第▲ｉｘ▼因子コンホメ−シヨン特異性モノクロ−ナル抗体
US6010902A (en)	1988-04-04	2000-01-04	Bristol-Meyers Squibb Company	Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
IL89491A0 (en)	1988-11-17	1989-09-10	Hybritech Inc	Bifunctional chimeric antibodies
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
AU649952B2 (en) *	1989-12-11	1994-06-09	Immunomedics Inc.	Method for antibody targeting of diagnostic or therapeutic agents
TW212184B (da)	1990-04-02	1993-09-01	Takeda Pharm Industry Co Ltd
JPH05184383A (ja)	1990-06-19	1993-07-27	Dainabotsuto Kk	二重特異性抗体
JPH05199894A (ja)	1990-08-20	1993-08-10	Takeda Chem Ind Ltd	二重特異性抗体および抗体含有薬剤
AU8507191A (en)	1990-08-29	1992-03-30	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
JPH05304992A (ja)	1991-06-20	1993-11-19	Takeda Chem Ind Ltd	ハイブリッド・モノクローナル抗体および抗体含有薬剤
DE69233528T2 (de)	1991-11-25	2006-03-16	Enzon, Inc.	Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
AU3328493A (en)	1991-12-17	1993-07-19	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
JPH05203652A (ja)	1992-01-28	1993-08-10	Fuji Photo Film Co Ltd	抗体酵素免疫分析法
JPH05213775A (ja)	1992-02-05	1993-08-24	Otsuka Pharmaceut Co Ltd	Ｂｆａ抗体
CA2102918C (en)	1992-03-11	2007-05-08	Joel R. Haynes	Genetic vaccine for immunodeficiency viruses
US6129914A (en)	1992-03-27	2000-10-10	Protein Design Labs, Inc.	Bispecific antibody effective to treat B-cell lymphoma and cell line
US5744446A (en) *	1992-04-07	1998-04-28	Emory University	Hybrid human/animal factor VIII
ES2301158T3 (es)	1992-07-24	2008-06-16	Amgen Fremont Inc.	Produccion de anticuerpos xenogenicos.
AU6819494A (en)	1993-04-26	1994-11-21	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
CA2143126A1 (en) *	1993-07-01	1995-01-12	Shamay Tang	Process for the preparation of factor x depleted plasma
DE122009000068I2 (de)	1994-06-03	2011-06-16	Ascenion Gmbh	Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
US5945311A (en)	1994-06-03	1999-08-31	GSF--Forschungszentrumfur Umweltund Gesundheit	Method for producing heterologous bi-specific antibodies
EP0771216B9 (en)	1994-07-11	2003-01-02	The Board Of Regents, The University Of Texas System	Methods and compositions for the specific coagulation of tumoral vasculature
CA2194907A1 (en)	1994-07-13	1996-02-01	Kouji Matsushima	Reshaped human antibody against human interleukin-8
CA2207869A1 (en)	1994-12-02	1996-06-06	Chiron Corporation	Method of promoting an immune response with a bispecific antibody
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
EP0822830B1 (en)	1995-04-27	2008-04-02	Amgen Fremont Inc.	Human anti-IL-8 antibodies, derived from immunized xenomice
WO1996034096A1 (en)	1995-04-28	1996-10-31	Abgenix, Inc.	Human antibodies derived from immunized xenomice
MA24512A1 (fr) *	1996-01-17	1998-12-31	Univ Vermont And State Agrienl	Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
AU720232B2 (en)	1996-07-19	2000-05-25	Amgen, Inc.	Analogs of cationic proteins
JPH10165184A (ja)	1996-12-16	1998-06-23	Tosoh Corp	抗体、遺伝子及びキメラ抗体の製法
DK0979281T3 (da)	1997-05-02	2005-11-21	Genentech Inc	Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
US20020062010A1 (en)	1997-05-02	2002-05-23	Genentech, Inc.	Method for making multispecific antibodies having heteromultimeric and common components
US20030207346A1 (en)	1997-05-02	2003-11-06	William R. Arathoon	Method for making multispecific antibodies having heteromultimeric and common components
DE19725586C2 (de)	1997-06-17	1999-06-24	Gsf Forschungszentrum Umwelt	Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper
US6207805B1 (en)	1997-07-18	2001-03-27	University Of Iowa Research Foundation	Prostate cell surface antigen-specific antibodies
US6342220B1 (en)	1997-08-25	2002-01-29	Genentech, Inc.	Agonist antibodies
TR200002885T2 (tr)	1998-04-03	2000-12-21	Chugai Seiyaku Kabushiki Kaisha	İnsan doku faktörüne (TF) karşı insanlaştırılmış antikor
EP1105427A2 (en)	1998-08-17	2001-06-13	Abgenix, Inc.	Generation of modified molecules with increased serum half-lives
AT411997B (de) *	1999-09-14	2004-08-26	Baxter Ag	Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
JP2002112369A (ja)	2000-10-03	2002-04-12	Sharp Corp	端末網制御装置
US20030008880A1 (en)	2001-05-02	2003-01-09	Pfizer Inc.	4-(2-Pyridyl) piperizines having 5HT7 receptor agonist activity
KR100988949B1 (ko)	2001-10-25	2010-10-20	제넨테크, 인크.	당단백질 조성물
DE10156482A1 (de) *	2001-11-12	2003-05-28	Gundram Jung	Bispezifisches Antikörper-Molekül
EP1500665B1 (en)	2002-04-15	2011-06-15	Chugai Seiyaku Kabushiki Kaisha	METHODS FOR CONSTRUCTING scDb LIBRARIES
JP4518941B2 (ja)	2002-04-26	2010-08-04	中外製薬株式会社	アゴニスト抗体のスクリーニング方法
EP1510943A4 (en)	2002-05-31	2007-05-09	Celestar Lexico Sciences Inc	INTERACTION PREDICTION DEVICE
DE602004021095D1 (de)	2003-01-21	2009-06-25	Chugai Pharmaceutical Co Ltd	Verfahren zum screening der leichten kette eines antikörpers
WO2005035754A1 (ja)	2003-10-14	2005-04-21	Chugai Seiyaku Kabushiki Kaisha	機能蛋白質を代替する二重特異性抗体
AU2003271174A1 (en)	2003-10-10	2005-04-27	Chugai Seiyaku Kabushiki Kaisha	Double specific antibodies substituting for functional protein
CN101198698B (zh)	2005-03-31	2014-03-19	中外制药株式会社	通过调节多肽缔合制备多肽的方法
EP1870458B1 (en)	2005-03-31	2018-05-09	Chugai Seiyaku Kabushiki Kaisha	sc(Fv)2 STRUCTURAL ISOMERS
CA2603264C (en)	2005-04-08	2017-03-21	Chugai Seiyaku Kabushiki Kaisha	Antibody substituting for function of blood coagulation factor viii
CN101237890A (zh)	2005-06-10	2008-08-06	中外制药株式会社	含有葡甲胺的蛋白质制剂的稳定剂及其利用
CN104761637B (zh)	2006-03-31	2021-10-15	中外制药株式会社	调控抗体血液动力学的方法
EP2009101B1 (en)	2006-03-31	2017-10-25	Chugai Seiyaku Kabushiki Kaisha	Antibody modification method for purifying bispecific antibody
DK2047863T3 (da)	2006-06-08	2013-09-16	Chugai Pharmaceutical Co Ltd	Middel til forebyggelse eller behandling af inflammatoriske sygdomme
CN101939425B (zh)	2007-09-26	2014-05-14	中外制药株式会社	抗il-6受体抗体
CN101874042B9 (zh)	2007-09-26	2019-01-01	中外制药株式会社	利用cdr的氨基酸取代来改变抗体等电点的方法
EP2275443B1 (en)	2008-04-11	2015-12-02	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
JP2011519279A (ja)	2008-05-01	2011-07-07	アムジエン・インコーポレーテツド	抗ヘプシジン抗体及び使用の方法
TWI440469B (zh)	2008-09-26	2014-06-11	Chugai Pharmaceutical Co Ltd	Improved antibody molecules

2003
- 2003-10-10 AU AU2003271174A patent/AU2003271174A1/en not_active Abandoned
- 2003-10-10 WO PCT/JP2003/013062 patent/WO2005035753A1/ja not_active Ceased
2004
- 2004-10-07 TW TW093130368A patent/TW200514790A/zh not_active IP Right Cessation
- 2004-10-08 CN CN200480036248.8A patent/CN1890369B/zh not_active Expired - Lifetime
- 2004-10-08 KR KR1020127033128A patent/KR101361437B1/ko not_active Expired - Lifetime
- 2004-10-08 EP EP04792180A patent/EP1688488B9/en not_active Expired - Lifetime
- 2004-10-08 NZ NZ546509A patent/NZ546509A/en not_active IP Right Cessation
- 2004-10-08 US US10/575,193 patent/US8062635B2/en active Active
- 2004-10-08 WO PCT/JP2004/014911 patent/WO2005035756A1/ja not_active Ceased
- 2004-10-08 ES ES16162353T patent/ES2865152T3/es not_active Expired - Lifetime
- 2004-10-08 JP JP2005514610A patent/JP5438880B2/ja not_active Expired - Lifetime
- 2004-10-08 EP EP16162353.3A patent/EP3085783B1/en not_active Expired - Lifetime
- 2004-10-08 EP EP10180356A patent/EP2289944A3/en not_active Withdrawn
- 2004-10-08 HU HUE16162353A patent/HUE053833T2/hu unknown
- 2004-10-08 BR BRPI0415230-1A patent/BRPI0415230B1/pt not_active IP Right Cessation
- 2004-10-08 DK DK16162353.3T patent/DK3085783T3/da active
- 2004-10-08 AU AU2004280421A patent/AU2004280421B2/en not_active Expired
- 2004-10-08 UA UAA200604899A patent/UA95438C2/ru unknown
- 2004-10-08 SI SI200432510T patent/SI3085783T1/sl unknown
- 2004-10-08 PT PT161623533T patent/PT3085783T/pt unknown
- 2004-10-08 RU RU2006115614/13A patent/RU2339696C2/ru active
- 2004-10-08 PL PL16162353T patent/PL3085783T3/pl unknown
- 2004-10-08 NO NO20160762A patent/NO345624B1/no unknown
- 2004-10-08 MX MXPA06003831A patent/MXPA06003831A/es active IP Right Grant
- 2004-10-08 CA CA2541671A patent/CA2541671C/en not_active Expired - Lifetime
- 2004-10-08 ES ES04792180T patent/ES2370250T3/es not_active Expired - Lifetime
- 2004-10-08 AT AT04792180T patent/ATE518952T1/de not_active IP Right Cessation
- 2004-10-08 DK DK04792180.4T patent/DK1688488T3/da active
2006
- 2006-04-05 IL IL174794A patent/IL174794A/en active IP Right Grant
- 2006-05-08 KR KR1020067008860A patent/KR101471194B1/ko not_active Expired - Lifetime
- 2006-05-09 NO NO20062087A patent/NO338686B1/no unknown
2011
- 2011-01-07 JP JP2011001733A patent/JP5490734B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
NO20160762A1 (no)	2006-07-07
KR101361437B1 (ko)	2014-02-11
RU2339696C2 (ru)	2008-11-27
EP2289944A2 (en)	2011-03-02
WO2005035756A1 (ja)	2005-04-21
NZ546509A (en)	2010-03-26
NO345624B1 (no)	2021-05-18
UA95438C2 (ru)	2011-08-10
EP1688488A1 (en)	2006-08-09
EP3085783B1 (en)	2021-01-27
CN1890369A (zh)	2007-01-03
HUE053833T2 (hu)	2021-07-28
CA2541671A1 (en)	2005-04-21
PT3085783T (pt)	2021-04-22
CA2541671C (en)	2015-01-06
JP5490734B2 (ja)	2014-05-14
AU2004280421A1 (en)	2005-04-21
EP2289944A3 (en)	2011-03-09
WO2005035753A1 (ja)	2005-04-21
KR20060111497A (ko)	2006-10-27
TWI354676B (da)	2011-12-21
BRPI0415230B1 (pt)	2023-01-10
EP1688488A4 (en)	2008-03-05
ATE518952T1 (de)	2011-08-15
US8062635B2 (en)	2011-11-22
KR101471194B1 (ko)	2014-12-09
DK3085783T3 (da)	2021-04-26
IL174794A0 (en)	2006-08-20
EP1688488B9 (en)	2012-03-21
BRPI0415230A (pt)	2006-12-12
AU2004280421B2 (en)	2011-06-02
IL174794A (en)	2011-11-30
KR20130018932A (ko)	2013-02-25
ES2370250T3 (es)	2011-12-13
JP2011137000A (ja)	2011-07-14
US20070041978A1 (en)	2007-02-22
JPWO2005035756A1 (ja)	2007-11-22
CN1890369B (zh)	2017-07-28
TW200514790A (en)	2005-05-01
EP1688488B1 (en)	2011-08-03
SI3085783T1 (sl)	2021-07-30
RU2006115614A (ru)	2007-11-20
ES2865152T3 (es)	2021-10-15
EP3085783A1 (en)	2016-10-26
MXPA06003831A (es)	2006-07-03
PL3085783T3 (pl)	2021-07-19
AU2003271174A1 (en)	2005-04-27
NO20062087L (no)	2006-07-07
JP5438880B2 (ja)	2014-03-12
NO338686B1 (no)	2016-09-26

Publication	Publication Date	Title
DK3085783T3 (da)	2021-04-26	Bispecifikt antistof som substitution for funktionelle proteiner
WO2004099249A3 (en)	2006-01-26	Optimized fc variants and methods for their generation
TW200738270A (en)	2007-10-16	Method of treating depression using a TNFα antibody
NO20063624L (no)	2006-10-03	FC region varianter
WO2005092925A3 (en)	2006-05-11	Immunoglobulin variants outside the fc region
IL195338A0 (en)	2011-08-01	Optimized fc variants and methods for their generation
WO2006118772A3 (en)	2007-05-31	Fcrn antibodies and uses thereof
GEP20166454B (en)	2016-04-11	Sclerostin binding agents
DK1766093T3 (da)	2011-10-03	Antistoffer mod clostridium difficile-toksiner og anvendelse deraf
DE602004025101D1 (de)	2010-03-04	Humane anti-humane cd3-bindungsmoleküle
MY143215A (en)	2011-03-31	Multifocal lenses for pre-presbyopic individuals
WO2006053301A3 (en)	2007-04-05	Fc variants with altered binding to fcrn
EA200870134A1 (ru)	2009-08-28	Частицы катализатора
EA200801172A1 (ru)	2008-12-30	Лиганды, имеющие специфичность связывания в отношении рецептора эпидермального фактора роста (egfr) и/или сосудистого эндотелиального фактора роста (vegf), и способы их применения
ATE497984T1 (de)	2011-02-15	Dimercaptanterminierte polythioetherpolymere und verfahren zu ihrer herstellung und verwendung
TW200606177A (en)	2006-02-16	Glycoprotein VI antibodies and methods thereof
CY1111505T1 (el)	2015-08-05	Φορεας για αποδοτικη επιλογη και/ή ωριμανση ενος αντισωματος και χρησεις αυτου
WO2007027805A3 (en)	2007-11-22	Method for generating anti-variable region monoclonal antibodies
BRPI0407680A (pt)	2006-03-01	métodos para diagnóstico de cáncer e diminuição de metástase por células cancerosas
WO2004069860A3 (en)	2005-03-24	Isg15-conjugated proteins
ATE414796T1 (de)	2008-12-15	Mittel zur herstellung von leder
EA200702353A1 (ru)	2008-02-28	Белковые гидролизаты, снижающие кровяное давление
EA200702543A1 (ru)	2008-06-30	Циклопентадиенильно-флуоренильные лиганды с углеродными мостиками
WO2007041684A3 (en)	2008-01-17	Ion flux in biological processes, and methods related thereto
ATE546157T1 (de)	2012-03-15	Anti-pecam-therapie zur unterdrückung von metastasen